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INTRODUCTION
Hydroxyurea is a cytoreductive agent indicated in the treat-
ment of variety of malignant and nonmalignant conditions.1 It 
generally is well tolerated with a side effect profile including 
bone marrow suppression, gastrointestinal, cutaneous manifes-
tations, and fever.2 We present a case of hydroxyurea-induced 
interstitial pneumonitis manifesting with symptoms of progres-
sively worsening shortness of breath and cough. The mechanism 
remains  unclear; however, our experience and literature review is 
indicative of an underlying hypersensitivity disorder. Clinicians 
should be aware of this unusual, yet life threatening side effect.
CASE REPORT
A 69-year-old man with polycythemia vera was start-
ed on hydroxyurea. Two months later, he presented with 
dyspnea and productive cough. Computed tomography 
(CT; Figures 1 and 2) of the chest showed diffuse, bilater-
al, ground glass opacities, bilateral pleural effusions, sep-
tal thickening, and subcentimeter pulmonary nodules. 
There was no history of notable environmental exposures. 
With no obvious etiology, an extensive investigation was ini-
tiated. Echocardiogram showed an ejection fraction of 45-50% 
with decreased left ventricular contractility. Pulmonary func-
tion testing revealed a new restrictive pattern with a low dif-
fusion capacity (Table 1). There was a concern for a cardiac eti-
ology versus hydroxyurea-induced lung injury. Hydroxyurea 
was tapered and discontinued. However, his symptoms con-
tinued to worsen resulting in acute hypoxic respiratory failure. 
Further evaluation included a bronchoscopy with bron-
choalveolar lavage (BAL) which showed 30% lymphocytes 
and negative viral and bacterial cultures. A right and left 
heart catheterization did not demonstrate evidence of coro-
nary artery disease or pulmonary hypertension. An autoim-
mune work up revealed an elevated ANA greater than 1280 
(diffuse pattern). The patient did not meet diagnostic cri-
teria for lupus as only two criteria were present at presenta-
tion: elevated ANA and evidence of serositis on imaging. 
The patient was initiated on high dose prednisone for two 
weeks. He had a remarkable improvement in his pulmonary 
symptoms. The clinical scenario was consistent with hydroxy-
urea-induced pneumonitis based on literature review and 
clinical, imaging, and BAL studies. A month later, pul-
monary function tests normalized with CT of the 
chest (Figures 3 and 4) showing near complete reso-
lution of diffuse infiltrates and pulmonary nodules.
Figure 1. CT chest showed small to moderate right and left pleural 
effusion. 
Figure 2. CT chest showed scattered pulmonary nodules in the right 
middle lobe. 
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Table 1. Initial pulmonary function tests showed mild restric-
tive pulmonary disease with a moderate defect in diffusion 
with noramlization on follow-up.
Pre-Bronchodilator
Spirometry Measure Predicted % Predicted
Forced Vital Capacity (FVC; 
L) 3.90 5.24 74
Forced Expiratory Volume 
in 1 second (FEV1; L) 2.79 3.88 72
FEV1/FVC (%) 71 74 97
Forced Expiratory Flow 
25% (L/sec) 7.04 8.29 85
Forced Expiratory Flow 
50% (L/sec) 2.31 1.60 50
Forced Expiratory Flow 
75% (L/sec) 0.53 1.45 36
Forced Expiratory Flow 
25 - 75% (L/sec) 1.67 2.95 57
Forced Expiratory Flow 
Max (L/sec) 11.20 8.66 129
Forced Inspiratory Vital 
Capacity (FIVC; L) 3.68
Forced Inspiratory Flow 
50% (L/sec) 0.76 4.40 04
Lung Volumes
Slow Vital Capacity 
(SVC; L) 3.91 5.24 75
Inspiratory Capacity (IC; L) 0.81 4.48 63
Total Gas Volume (TGV; L) 3.13 4.26 74
Residual Volume (RV; L) 2.30 2.68 86
Total Lung Capacity 
(TLC; L) 6.03 7.93 76
RV/TLC (L) 30 35 109
Diffusions
Lung Diffusion Capacity 
Testing (DLCO; L) 16.15 28.20 57
Alveolar Volume (VA; L) 5.72 7.69 74
DLCO/VA (L) 2.82 3.70 76
DISCUSSION
Hydroxyurea is useful in controlling polycythemia vera-re-
lated symptoms, splenomegaly, leukocytosis, thrombocytosis, 
and hematocrit. However, hydroxyurea-treated patients can 
become resistant or experience unacceptable adverse effects 
(hyproxyurea intolerance), including skin ulcers, a reduction 
in blood cells, gastrointestinal problems, oral ulcers, stomatitis, 
hyperkeratosis, or actinic keratosis.3 Hydroxyurea pulmonary 
toxicity is rare; reported cases consist mainly of acute alveoli-
tis or interstitial pneumonitis. Quintás-Cardama et al.1 report-
ed the first case of acute alveolitis induced by hydroxyurea.
 
Figure 3. Comparative CT of the chest showed resolution of the left 
pleueral effusion. 
Figure 4. Comparative CT of the chest showed resolution of the right 
pulmonary nodules. 
A few case reports can be found in the literature to sup-
port this diagnosis.3-5 The onset of symptoms develops within 
4 - 12 weeks. Variation in presentation of hydroxyurea-induced 
lung injury exists and it remains a diagnosis of exclusion. Ini-
tial work-up should assess for infection, cardiac etiology, col-
lagen vascular disease and environmental exposures. Lung 
biopsy was performed in some cases, however, it is not indi-
cated if the suspicion is high.3,4 Treatment includes withdraw-
al of offending agent and concurrent use of corticosteroids.
CONCLUSION
Hydroxyurea should be considered in differ-
ential diagnosis of atypical interstitial pneumoni-
tis. If not diagnosed, hydroxyurea-induced intersti-
tial pneumonitis may lead to acute respiratory failure.
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